Syncona Limited Release of Key Information Document
January 02 2018 - 4:47AM
UK Regulatory
TIDMSYNC
Syncona Limited
Release of Key Information Document
02 January 2017
Syncona Ltd ("Syncona"), a leading healthcare company focused on investing in
and building global leaders in life science, has released a Key Information
Document ("KID") in compliance with the Packaged Retail and Insurance-based
Investment Products ("PRIIPs") Regulation that comes into effect in January
2018.
The KID is available on the Company's website in the Investor Relations
section.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031
Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com
Forward-looking statements - this announcement contains certain forward-looking
statements with respect to the portfolio of investments of Syncona Ltd. These
statements and forecasts involve risk and uncertainty because they relate to
events and depend upon circumstances that may or may not occur in the future.
There are a number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these forward-looking
statements and forecasts. Nothing in this announcement should be construed as a
profit forecast.
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of healthcare
while generating superior returns for shareholders. Our current investment
portfolio consists of seven high quality companies in life science and a
leading range of fund investments. We seek to partner with the best, brightest
and most ambitious minds in science to build globally competitive businesses.
We are established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients in areas of
high unmet need.
Our market leading funds portfolio seeks to generate superior returns by
investing in long only and alternative investment funds. This represents a
productively deployed evergreen funding base which enables us to take a long
term approach to investing in life sciences as we target the best new
opportunities and support our existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business. We make a donation of
0.3% of Net Asset Value to a range of charities each year.
END
(END) Dow Jones Newswires
January 02, 2018 04:47 ET (09:47 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024